Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    PerkinElmer Receives FDA Emergency Use Authorization for Combination COVID/Flu/RSV Test

    By Global Biodefense StaffOctober 7, 2021
    SARS-CoV-2. Credit: NIAID
    Share
    Facebook LinkedIn Reddit Email

    Multiplex RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and RSV

    PerkinElmer, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.

    Qualified laboratories can immediately begin using this single test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs and mid-turbinate swabs.

    The company said in a news release that the advantage of a multi-analyte test such as the PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 assay allows laboratories to conserve precious resources by avoiding multiple tests on samples collected from individuals suspected of respiratory viral infection consistent with COVID-19.

    “As we enter the flu season, this timely emergency use authorization will be welcome by laboratories that are looking to test for common respiratory illnesses alongside COVID-19,” PerkinElmer managing director of specialty diagnostics Arvind Kothandaraman said in the release. “The new test will help to alleviate confusion arising from similar symptoms caused by these infections and reduce further strain on the healthcare system during a pandemic.”

    COVID-19, flu and RSV infections are highly contagious and often cannot be differentiated based on symptoms alone. The U.S. Centers for Disease Control and Prevention encourages COVID-19 testing laboratories to adopt a multiplex method that facilitates detection and differentiation of SARS-CoV-2 and influenza viruses.

    Adapted from PerkinElmer press release.

    COVID-19 Editor Pick SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBreakthrough Results for Dengue Antiviral: Janssen Compound Shows Promise Against All Serotypes
    Next Article Bacteria Break-up May Block Bubonic Plague

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    Global Biodefense places cookies on your device to enable the best user experience. By using our website, you agree to placement of these cookies. To learn more, read our Privacy Policy.OKPrivacy Policy